STOCK TITAN

Amneal (AMRX) director Jeffrey George exercises 34,819 RSUs, receives 19,824 new units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amneal Pharmaceuticals director Jeffrey P. George reported routine equity compensation activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares and bringing his direct holdings to 344,614 shares.

These 34,819 restricted stock units were previously granted and each unit represented a right to receive one share of Class A Common Stock upon vesting. On May 6, 2026, he was also awarded 19,824 new restricted stock units, which will convert into Class A shares when they vest under the company’s standard vesting schedule tied to the annual meeting and one‑year anniversary of grant.

Positive

  • None.

Negative

  • None.
Insider George Jeffrey P.
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 34,819 $0.00 --
Exercise Class A Common Stock 34,819 $0.00 --
Grant/Award Restricted Stock Units 19,824 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Class A Common Stock — 344,614 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
RSUs exercised 34,819 units Converted into Class A Common Stock on May 7, 2026
Shares held after exercise 344,614 shares Class A Common Stock held directly after May 7, 2026 transaction
New RSU grant 19,824 units Restricted Stock Units granted on May 6, 2026
Prior RSU grant 34,819 units Granted on May 6, 2025, vesting on May 7, 2026
Exercise price per RSU $0.00 per unit Conversion of restricted stock units into Class A Common Stock
Restricted Stock Units financial
"The filing reports transactions in “Restricted Stock Units” tied to Class A Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Class A Common Stock financial
"Each restricted stock unit converts into one share of the Issuer's Class A Common Stock."
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share."
annual meeting of stockholders financial
"Restricted stock units vest around the issuer's first annual meeting of stockholders following the grant."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
George Jeffrey P.

(Last)(First)(Middle)
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock05/07/2026M34,819A(1)344,614D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/07/2026M34,819 (2) (2)Class A Common Stock34,819$00D
Restricted Stock Units(1)05/06/2026A19,824 (3) (3)Class A Common Stock19,824$019,824D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
2. On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.
3. Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
Remarks:
/s/ Denis Butkovic, Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amneal Pharmaceuticals (AMRX) director Jeffrey P. George report on this Form 4?

He reported routine equity compensation activity. On May 7, 2026, he exercised 34,819 restricted stock units into Class A Common Stock and, on May 6, 2026, he received a new grant of 19,824 restricted stock units as part of his director compensation.

How many Amneal (AMRX) shares does Jeffrey P. George hold after these transactions?

After exercising 34,819 restricted stock units into Class A Common Stock, Jeffrey P. George directly holds 344,614 shares. These holdings reflect his position following the reported transactions and do not include the 19,824 unvested restricted stock units granted on May 6, 2026.

What restricted stock unit grants were disclosed for Amneal (AMRX) director Jeffrey P. George?

The filing shows a grant of 34,819 restricted stock units on May 6, 2025, which vested on May 7, 2026, and a separate grant of 19,824 restricted stock units on May 6, 2026. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock.

How do Amneal (AMRX) restricted stock units work for Jeffrey P. George?

Each Amneal restricted stock unit represents a contingent right to receive one Class A Common share upon vesting. The units vest on the later of the day immediately before the first annual shareholder meeting after grant and the day immediately following the first anniversary of the grant date.

Were there any open‑market buys or sells by Jeffrey P. George in this Amneal (AMRX) Form 4?

No open‑market buys or sells are reported. The Form 4 shows only a derivative exercise of 34,819 restricted stock units into Class A Common Stock and a new grant of 19,824 restricted stock units, both recorded as compensation-related acquisitions, not market trades.

What vesting terms apply to the Amneal (AMRX) restricted stock units reported in this filing?

The restricted stock units vest on the later of two dates: the day immediately preceding Amneal’s first annual meeting of stockholders following the grant date and the day immediately following the first anniversary of the grant date. Once vested, each unit converts into one Class A share.